Understanding the aetiology of NF-κB activation can provide a rationale for targeting NF-κB in the ABC subtype of DLBCL that is characterized by constitutive NF-κB activation and shows resistance to current therapeutic modalities. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.